Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

References

• Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med. 2011;3(3):14. doi:10.1186/gm22821392406
   PubMed Web of Science ®Google Scholar
• Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146(6):1547–1553. doi:10.1053/j.gastro.2014.01.05924503131
   PubMed Web of Science ®Google Scholar
• Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi:10.1038/nrdp.2016.2027158839
   PubMed Web of Science ®Google Scholar
• Crowther GS, Wilcox MH. Antibiotic therapy and Clostridium difficile infection – primum non nocere - first do no harm. Infect Drug Resist. 2015;8:333–337. doi:10.2147/IDR.S8722426396535
   PubMed Web of Science ®Google Scholar
• Knecht H, Neulinger SC, Heinsen FA, et al. Effects of beta-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PLoS One. 2014;9(2):e89417. doi:10.1371/journal.pone.008941724586762
   PubMed Web of Science ®Google Scholar
• Panda S, El Khader I, Casellas F, et al. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014;9(4):e95476. doi:10.1371/journal.pone.009547624748167
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Olsen MA, Stwalley D, et al. Identification of medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLoS One. 2016;11(2):e0146822. doi:10.1371/journal.pone.014682226859403
   PubMed Web of Science ®Google Scholar
• Kuntz JL, Smith DH, Petrik AF, et al. Predicting the risk of Clostridium difficile Infection upon admission: a score to identify patients for antimicrobial stewardship efforts. Perm J. 2016;20(1):20–25. doi:10.7812/TPP/15-04926845084
   PubMedGoogle Scholar
• Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2015;69:881–891. doi:10.1093/jac/dkt477
   Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48. doi:10.1093/cid/cir30121653301
   PubMed Web of Science ®Google Scholar
• Vincent C, Manges AR. Antimicrobial use, human gut microbiota and Clostridium difficile colonization and infection. Antibiotics (Basel). 2015;4(3):230–253. doi:10.3390/antibiotics403023027025623
   PubMedGoogle Scholar
• Wieczorkiewicz JT, Lopansri BK, Cheknis A, et al. Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone- and macrolide-resistant epidemic C. difficile strain BI/NAP1/027. Antimicrob Agents Chemother. 2016;60(1):418–423. doi:10.1128/AAC.01820-1526525793
   PubMed Web of Science ®Google Scholar
• Karachalios G, Charalabopoulos K. Biliary excretion of antimicrobial drugs. Chemotherapy. 2002;48(6):280–297. doi:10.1159/00006971212673103
   PubMed Web of Science ®Google Scholar
• Kokai-Kun JF, Roberts T, Coughlin O, et al. The oral beta-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies. Antimicrob Agents Chemother. 2017;61(1):3. doi:10.1128/AAC.02197-16
   Web of Science ®Google Scholar
• Johanesen PA, Mackin KE, Hutton ML, et al. Disruption of the gut microbiome: clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel). 2015;6(4):1347–1360. doi:10.3390/genes604134726703737
   PubMed Web of Science ®Google Scholar
• van Schaik W. The human gut resistome. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140087. doi:10.1098/rstb.2014.008725918444
   PubMed Web of Science ®Google Scholar
• Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51. doi:10.1038/nrmicro338025435309
   PubMed Web of Science ®Google Scholar
• Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther. 2014;12(10):1221–1236. doi:10.1586/14787210.2014.95609225199988
   PubMed Web of Science ®Google Scholar
• Dumford DM, Nerandzic M, Chang S, Richmond MA, Donskey C. Epidemiology of Clostridium difficile and vancomycin-resistant Enterococcus colonization in patients on a spinal cord injury unit. J Spinal Cord Med. 2011;34(1):22–27. doi:10.1179/107902610x1288342281382221528623
   PubMed Web of Science ®Google Scholar
• Fujitani S, George WL, Morgan MA, Nichols S, Murthy AR. Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections. Am J Infect Control. 2011;39(3):188–193. doi:10.1016/j.ajic.2010.10.02421458682
   PubMed Web of Science ®Google Scholar
• Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174–1182. doi:10.1182/blood-2014-02-55472524939656
   PubMed Web of Science ®Google Scholar
• Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16(11):1576–1581. doi:10.1016/j.bbmt.2010.05.00820685257
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR. Epidemiology and management of emerging drug-resistant gram-negative bacteria: extended-spectrum beta-lactamases and beyond. Urol Clin North Am. 2015;42(4):493–505. doi:10.1016/j.ucl.2015.05.00526475946
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis. 2011;11(5):381–393. doi:10.1016/S1473-3099(11)70056-121530894
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236. doi:10.1016/S1473-3099(09)70054-419324295
   PubMed Web of Science ®Google Scholar
• Zmarlicka MT, Nailor MD, Nicolau DP. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist. 2015;8:297–309. doi:10.2147/IDR.S3918626345624
   PubMed Web of Science ®Google Scholar
• Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol. 2013;303(6–7):298–304. doi:10.1016/j.ijmm.2013.02.00123499304
   PubMed Web of Science ®Google Scholar
• McGann P, Snesrud E, Maybank R, et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the USA. Antimicrob Agents Chemother. 2016;60(7):4420–4421.27230792
   PubMed Web of Science ®Google Scholar
• Kaleko M, Bristol JA, Hubert S, et al. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe. 2016;41:58–67. doi:10.1016/j.anaerobe.2016.05.01527262694
   PubMed Web of Science ®Google Scholar
• Connelly S, Bristol JA, Hubert S, et al. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model. J Appl Microbiol. 2017;123(1):66–79. doi:10.1111/jam.1343228245091
   PubMed Web of Science ®Google Scholar
• Kokai-Kun JF, Roberts T, Coughlin O, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019;19(5):487–496. doi:10.1016/S1473-3099(18)30731-X30885591
   PubMed Web of Science ®Google Scholar
• Kokai-Kun JF, Sarver JL, Carman RJ. Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection. Anaerobe. 2018;53:30–33. doi:10.1016/j.anaerobe.2018.07.00229981838
   PubMed Web of Science ®Google Scholar
• Kokai-Kun JF, Connelly S. Ribaxamase, an orally administered β-lactamase, protects the gut microbiome in patients treated with ceftriaxone. J Trans Sci. 2019;6:1–9.
   Google Scholar
• Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r6021702898
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Akram AR, Singanayagam A, Wilcox MH, Hill AT. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Infect. 2016;73(1):45–53. doi:10.1016/j.jinf.2016.04.00827105657
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi:10.1136/gutjnl-2015-31037626657899
   PubMed Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–756. doi:10.1136/gutjnl-2015-31086126719299
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi:10.1056/NEJMoa140891325714160
   PubMed Web of Science ®Google Scholar
• Zapata HJ, Quagliarello VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 2015;63(4):776–781. doi:10.1111/jgs.1331025851728
   PubMed Web of Science ®Google Scholar
• Fernandez L, Hancock RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25(4):661–681. doi:10.1128/CMR.00043-1223034325
   PubMed Web of Science ®Google Scholar
• Parker AC, Smith CJ. Genetic and biochemical analysis of a novel Ambler class A beta-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob Agents Chemother. 1993;37(5):1028–1036. doi:10.1128/AAC.37.5.10288517690
   PubMed Web of Science ®Google Scholar
• Madinier I, Fosse T, Giudicelli J, Labia R. Cloning and biochemical characterization of a class A beta-lactamase from Prevotella intermedia. Antimicrob Agents Chemother. 2001;45(8):2386–2389. doi:10.1128/AAC.45.8.2386-2389.200111451705
   PubMed Web of Science ®Google Scholar
• Jolivet-Gougeon A, Tamanai-Shacoori Z, Desbordes L, Burggraeve N, Cormier M, Bonnaure-Mallet M. Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea. J Clin Microbiol. 2004;42(2):888–890. doi:10.1128/JCM.42.2.888-890.200414766881
   PubMed Web of Science ®Google Scholar
• Meggersee R, Abratt V. The occurrence of antibiotic resistance genes in drug resistant Bacteroides fragilis isolates from Groote Schuur Hospital, South Africa. Anaerobe. 2015;32:1–6. doi:10.1016/j.anaerobe.2014.11.00325460195
   PubMed Web of Science ®Google Scholar
• Molina J, Barrantes G, Quesada-Gomez C, Rodriguez C, Rodriguez-Cavallini E. Phenotypic and genotypic characterization of multidrug-resistant Bacteroides, Parabacteroides spp., and Pseudoflavonifractor from a Costa Rican hospital. Microb Drug Resist. 2014;20(5):478–484. doi:10.1089/mdr.2013.018024606061
   PubMed Web of Science ®Google Scholar
• Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42 Suppl 1(SUPPL1):S25–S34. doi:10.1086/49171116323116
   PubMed Web of Science ®Google Scholar
• Soki J, Gonzalez SM, Urban E, Nagy E, Ayala JA. Molecular analysis of the effector mechanisms of cefoxitin resistance among Bacteroides strains. J Antimicrob Chemother. 2011;66(11):2492–2500. doi:10.1093/jac/dkr33921873290
   PubMed Web of Science ®Google Scholar
• Kierzkowska M, Majewska A, Szymanek-Majchrzak K, Sawicka-Grzelak A, Mlynarczyk A, Mlynarczyk G. The presence of antibiotic resistance genes and bft genes as well as antibiotic susceptibility testing of Bacteroides fragilis strains isolated from inpatients of the Infant Jesus Teaching Hospital, Warsaw during 2007–2012. Anaerobe. 2019;56:109–115. doi:10.1016/j.anaerobe.2019.03.00330844502
   PubMed Web of Science ®Google Scholar
• Aldridge KE, Ashcraft D, O’Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother. 2003;47(1):148–153. doi:10.1128/AAC.47.1.148-153.200312499183
   PubMed Web of Science ®Google Scholar
• Ferreira LQ, Avelar KE, Vieira JM, et al. Association between the cfxA gene and transposon Tn4555 in Bacteroides distasonis strains and other Bacteroides species. Curr Microbiol. 2007;54(5):348–353. doi:10.1007/s00284-006-0411-017486409
   PubMed Web of Science ®Google Scholar
• Novais RC, Chaves MC, Gonzalez AGM, Andrade JRC. Molecular investigation of tRNA genes integrity and its relation to pathogenicity islands in Shiga toxin-producing Escherichia coli (STEC) strains. Genet Mol Biol. 2004;27:589–593. doi:10.1590/S1415-47572004000400020
   Web of Science ®Google Scholar
• Garcia N, Gutierrez G, Lorenzo M, Garcia JE, Piriz S, Quesada A. Genetic determinants for cfxA expression in Bacteroides strains isolated from human infections. J Antimicrob Chemother. 2008;62(5):942–947. doi:10.1093/jac/dkn34718775891
   PubMed Web of Science ®Google Scholar
• Iwahara K, Kuriyama T, Shimura S, et al. Detection of cfxA and cfxA2, the beta-lactamase genes of Prevotella spp., in clinical samples from dentoalveolar infection by real-time PCR. J Clin Microbiol. 2006;44(1):172–176. doi:10.1128/JCM.44.1.172-176.200616390966
   PubMed Web of Science ®Google Scholar
• Casadewall B, Courvalin P. Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339. J Bacteriol. 1999;181(12):3644–3648. doi:10.1128/JB.181.12.3644-3648.199910368136
   PubMed Web of Science ®Google Scholar
• Depardieu F, Foucault ML, Bell J, et al. New combinations of mutations in VanD-Type vancomycin-resistant Enterococcus faecium, Enterococcus faecalis, and Enterococcus avium strains. Antimicrob Agents Chemother. 2009;53(5):1952–1963. doi:10.1128/AAC.01348-0819258279
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi:10.1038/nature0882120203603
   PubMed Web of Science ®Google Scholar
• Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784–791. doi:10.1001/jamainternmed.2017.021228346595
   PubMed Web of Science ®Google Scholar
• Binta B, Patel M. Detection of cfxA2, cfxA3, and cfxA6 genes in beta-lactamase producing oral anaerobes. J Appl Oral Sci. 2016;24(2):142–147. doi:10.1590/1678-77572015046927119762
   PubMed Web of Science ®Google Scholar
• Ambrose KD, Nisbet R, Stephens DS. Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother. 2005;49(10):4203–4209. doi:10.1128/AAC.49.10.4203-4209.200516189099
   PubMed Web of Science ®Google Scholar
• Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii– the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol. 2008;46(3):257–267. doi:10.2478/v10042-008-0056-x19056528
   PubMed Web of Science ®Google Scholar